To many biopharmaceutial executives and investors, the start of 2026 felt like a new dawn. A lengthy pullback finally abated towards the end of 2025, as a wave of dealmaking, financings and positive clinical trial readouts lifted drug companies and revitalized broader investor interest. Yet that newfound optimism is also mixed with an underlying tension. At the J.P. Morgan Healthcare Conference this January — a meeting that serves as the industry’s yearly barometer — attendees wrestled with whether to feel confident or skeptical about what’s to come. The answers will shape the industry’s fortunes this year, as BioPharma Dive details in the stories below.